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Abstract
The majority of the 17 million women globally that are estimated to be infected with HIV live in 
Sub-Saharan Africa. Worldwide, HIV-related causes contributed to 19 000–56 000 maternal 
deaths in 2011 (6%–20% of maternal deaths). HIV-infected pregnant women have two to 10 times 
the risk of dying during pregnancy and the postpartum period compared with uninfected pregnant 
women. Many of these deaths can be prevented with the implementation of high-quality obstetric 
care, prevention and treatment of common co-infections, and treatment of HIV with ART. The 
paper summarizes what is known about HIV disease progression in pregnancy, specific causes of 
HIV-related maternal deaths, and the potential impact of treatment with antiretroviral therapy on 
maternal mortality. Recommendations are proposed for improving maternal health and decreasing 
maternal mortality among HIV-infected women based on existing evidence.
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1. Introduction
An estimated 17 million women globally are living with HIV. The majority of these women 
live in Sub-Saharan Africa and are of reproductive age (15–49 years) [1]. Estimates of 
maternal death due to HIV-related causes vary widely. In 2011, HIV-related causes 
contributed to between 19 000 [2] and 56 000 maternal deaths [3], accounting for between 
6% and 20% of maternal deaths globally and likely a much higher proportion of deaths in 
Sub-Saharan Africa [2,3]. Globally over the past two decades, maternal mortality has 
decreased. However, reductions in Sub-Saharan Africa have not kept pace with other parts 
of the world, making it unlikely that many countries in this region will achieve Millennium 
Development Goal 5 (MDG 5). The HIV pandemic has contributed to this lack of progress. 
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HIV-infected pregnant women have two to 10 times the risk of dying during pregnancy and 
the postpartum period compared with uninfected pregnant women [4–8].
The present paper summarizes what is known about HIV disease progression in pregnancy, 
the specific causes of HIV-related maternal deaths, and the potential impact of treatment 
with antiretroviral therapy (ART) on maternal mortality. We propose recommendations for 
improving maternal health and decreasing maternal mortality among HIV-infected women 
based on existing evidence.
2. HIV disease progression in pregnancy
Pregnancy does not appear to accelerate the progression of HIV disease. Although some of 
the studies addressing this issue come from high-income countries where women had 
various treatment options [9], studies from low-income countries in which there was no 
treatment available report similar findings [9]. While studies generally agree that there is no 
HIV disease progression during pregnancy, there is a suggestion that pregnancy (or perhaps 
breastfeeding) may accelerate disease progression after delivery [10]. There is no evidence 
of an increased risk of deaths due to HIV among HIV-infected pregnant women compared 
with HIV-infected nonpregnant women [11]. In fact, HIV-infected women who are not 
pregnant have significantly higher mortality rates than their pregnant counterparts [4,12]. 
Advanced HIV disease is associated with lower fertility rates. HIV-infected pregnant 
women are generally healthier than nonpregnant HIV-infected women and they are less 
likely to be in the later stages of disease and as a group have less HIV-attributable mortality 
than nonpregnant HIV-infected women [5].
3. Causes of maternal death among HIV-infected women
WHO defines maternal deaths as those that occur during pregnancy or within 42 days of 
termination of pregnancy from either direct or indirect causes [13]. Deaths in HIV-infected 
pregnant women arise from both direct causes (those directly caused by the pregnancy or its 
management) and indirect causes (those in which the pregnancy contributed to a death from 
another condition), which are largely infectious in low-income settings. The direct and 
indirect causes are each responsible for a variable proportion of maternal deaths, depending 
upon the region, setting, and prevalence of other infectious diseases. The proportion of 
deaths attributed to indirect causes has been reported to be greater than 50% in some 
settings, and some of the highest contributors to indirect deaths in the HIV-infected pregnant 
population include AIDS, tuberculosis, malaria, and pneumonia, among others [8]. The 
direct causes that contribute to a greater risk of death in the HIV-infected compared with the 
uninfected pregnant woman include puerperal sepsis and sepsis related to abortion [8].
4. HIV-related maternal mortality: Tuberculosis, malaria, and pneumonia
Nonpregnancy related infections, particularly tuberculosis, malaria, and pneumonia, are 
important causes of maternal death in HIV-infected pregnant or postpartum women. There 
are physiologic and immunologic changes in pregnancy that can alter susceptibility to and 
severity of infectious diseases. Pulmonary and cardiac physiologic changes may contribute 
to an increased risk of respiratory diseases, and a shift from cell-mediated immunity toward 
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humoral immunity during pregnancy may increase susceptibility to some infections [14]. 
Tuberculosis is a leading cause of maternal mortality in settings with a high HIV burden, 
and while the exact burden of HIV and tuberculosis co-infection in pregnant women is not 
known, several studies have demonstrated high HIV prevalence among maternal deaths 
attributed to tuberculosis. In a retrospective study in Zambia, 25% of maternal deaths were 
due to tuberculosis and 92% of these mothers were co-infected with HIV [15,16]. Co-
infection with tuberculosis and HIV is particularly harmful in that HIV increases 
reactivation of tuberculosis and increases tuberculosis mortality, and the tuberculosis 
infection can cause a decrease in CD4 cells and an increase in viral replication [17]. 
Pregnant women infected with both tuberculosis and HIV have two to three times the risk of 
dying compared with pregnant women infected with tuberculosis alone [18,19]. Effective 
screening, prevention, and treatment measures exist for tuberculosis and can be 
accomplished during pregnancy if these activities are prioritized. Initiating active 
tuberculosis case-finding into existing prenatal clinics in Soweto, South Africa, through 
administration of a straightforward five-question screening tool led to discovery of a high 
burden of active tuberculosis among HIV-infected pregnant women [11]. Tuberculosis 
mortality among HIV-infected pregnant women can be prevented by integrating tuberculosis 
screening, isoniazid prophylactic treatment, tuberculosis treatment, and ART within prenatal 
care services [11].
Co-infection with HIV and malaria is also common in areas with a high prevalence of each 
of these diseases. HIV infection is associated with an increase in both the prevalence and 
severity of malaria, as well as an impaired response to malaria treatment [20]. The risks of 
severe anemia and maternal death in pregnant women co-infected with HIV and malaria are, 
respectively, three and five times those of pregnant women infected with malaria alone 
[21,22]. Established malaria prevention guidelines for pregnant women, including those with 
HIV co-infection, call for daily co-trimoxazole or intermittent prevention therapy with 
sulfadoxine and pyrimethamine; however, these prevention strategies continue to face 
barriers, largely due to constraints on health system infrastructure, outreach ability, and 
human and financial resources, which perpetuate the risk of complications and death from 
co-infection [20,23].
Pneumonia is a leading cause of indirect maternal death among HIV-infected pregnant 
women, yet a limited understanding of the specific causes of pneumonia exists [8]. A likely 
combination of etiologies include community acquired pneumonia, Pneumocystis jirovecii 
pneumonia, tuberculosis, and respiratory failure of unknown etiology; yet specific pathogens 
are rarely reported in the literature, limiting development and implementation of cause-
specific interventions [8].
5. Direct obstetric complications and HIV-related maternal mortality
While the majority of HIV-related maternal deaths are from indirect causes, there is 
evidence that women infected with HIV have an increased risk of death from some obstetric 
complications. Findings from several studies suggest an increased risk of development of 
and mortality from both puerperal sepsis, especially after cesarean delivery, and abortion-
related sepsis. HIV infection was shown to be a major risk factor for mortality due to 
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puerperal sepsis and abortion-related sepsis in the 2005–2007 South African confidential 
enquiries report [8], and HIV-infected pregnant women have approximately six times the 
risk of developing puerperal sepsis and three times the risk of death from sepsis after 
delivery [8,24–26]. While data on the topic are limited, this risk is also seen in high-income 
countries despite wide access to and treatment with ART [27].
6. Effect of antiretroviral treatment on maternal mortality
While there has been an increase in the number of pregnant HIV-infected women who have 
access to and use ART in the past five years, there is a jarring lack of published data 
demonstrating the effect of ART on maternal mortality. In studies that do address the effects 
of ART on maternal survival, conclusions have been inconsistent. In an observational study 
that reviewed records of HIV-infected women receiving prenatal care in Malawi and 
Mozambique, ART for prevention of mother-to-child transmission reduced the maternal 
mortality ratio (MMR) 13-fold overall. Furthermore, the MMR showed a dose– response 
effect, with the lowest MMR among those women who received ART for more than 90 days 
[28]. However, the study did not compare the MMR for HIV-infected women with those 
who were uninfected; therefore it is not known if the risk was reduced to the general 
population level. In a recent systematic review addressing the contribution of HIV to 
pregnancy related death, no difference in the pooled relative risk of mortality was seen in 
HIV-infected pregnant or postpartum women in studies done during a time when ART was 
available compared with studies done in an era in which ART was not available [7,12]. 
However, as pointed out in that review, the studies varied by region and criteria for initiation 
of ART, limiting ART to women with very low CD4 counts. Most pregnant women would 
either not have had access to ART or received it only at the time of delivery. It is likely that 
the relative risk of death would be lower in treated pregnant women if all HIV-infected 
pregnant and postpartum women were on ART [7].
Despite improved access to ART in many countries in Sub-Saharan Africa over the past 
several years, including improved availability to pregnant women, most of the available 
published studies that report maternal deaths comprised women who had little or no 
exposure to ART, or the investigators were unaware of treatment status. While ART will 
certainly reduce HIV-related maternal deaths, the optimal timing of the initiation of 
treatment and the extent to which treatment will prevent mortality during pregnancy have 
not been determined.
7. Discussion and recommendations
There were an estimated 19 000–56 000 maternal deaths attributed to HIV-related causes in 
2011, contributing to some 6%–20% of all maternal deaths worldwide. The contributors to 
these deaths are multifactorial and include infectious etiologies, complications of the 
pregnancy itself, contextual and structural barriers to care, and likely biological interactions 
that are not well understood. However, we do know that many of these deaths can be 
prevented with the implementation of high-quality obstetric care, prevention and treatment 
of common co-infections, and treatment of HIV with ART.
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Identification and reduction of barriers to HIV testing and treatment in pregnancy, including 
stigma associated with HIV infection and the poor care that can result from this stigma, must 
be addressed as part of an overall strategy. Fully understanding the links among HIV 
infection, pregnancy, and stigma associated with HIV will be important to decrease the risk 
of untreated HIV disease and increased mortality. Access to early prenatal care, integration 
of prenatal, HIV, tuberculosis, and malaria care, and initiation of ART according to 
established WHO guidelines would improve availability of comprehensive pregnancy care 
and reduce maternal morbidity and mortality related to HIV in pregnancy.
Provision of good quality, evidence-based peripartum care and adherence to best surgical 
and infection prevention practices, including routine preoperative antibiotic prophylaxis, can 
reduce the direct obstetric complications caused by sepsis in HIV-infected and uninfected 
women. Where abortion is legal, education of women regarding the availability of safe 
services will save lives, and where safe abortion is not legally available, it is important to 
offer prompt, high-quality post-abortion care to save women's lives. Integration of family 
planning services into HIV care and both immediate and extended postpartum care will be 
key strategies to improve both maternal and infant survival, by limiting pregnancies to 
planned and wanted pregnancies and decreasing the opportunity for vertical transmission.
Improved maternal mortality surveillance systems, which include causes of death, HIV 
status, and ART status, will allow for a more complete understanding of the contribution of 
specific disease entities to maternal mortality in HIV-infected women, missed opportunities 
for testing and treatment, and the impact of ART treatment on maternal mortality reduction. 
To further address the many questions that remain, it will be important for the HIV and 
maternal health communities to converge and identify gaps in the collective understanding 
of HIV infection and maternal death. A research agenda could be created, and may include 
such questions as: what is the impact of ART on maternal mortality overall, and specifically 
on peripartum and postabortion sepsis? What is optimal, comprehensive care for HIV-
infected women, and what are the best strategies for integrating HIV, tuberculosis, malaria, 
and family planning into prenatal and postnatal care? How does stigma manifest as a barrier 
to status disclosure and initiation and continuation of treatment, in particular in HIV-infected 
pregnant women? And finally, what are optimal testing, prophylaxis, and treatment 
strategies for women who have HIV co-infection with malaria and tuberculosis?
HIV-infected women are much more likely to die during or soon after pregnancy than their 
HIV-uninfected counterparts. These deaths are preventable through the provision of good 
quality prenatal care that includes ART and essential obstetric care. MDG 5 and the new call 
to eliminate preventable maternal mortality cannot be achieved unless we address the needs 
of HIV-infected women. These needs cannot be met without the development of a high-
quality system of care for all women—a system that couples evidence-based best practices 
with emerging research findings, and incorporates political, community, and cultural will to 
value and prioritize the care of pregnant and post-partum women, including those infected 
with HIV.
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